Screener
4D Molecular Therapeutics FDMT Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value, 300,000,000 shares authorized at March 31, 2026 and December 31, 2025; 52,271,648 and 57,607,874 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 5 | 6 |
| Additional paid-in-capital | 1,237,075 | 1,221,235 |
| Accumulated other comprehensive gain (loss) | (180) | 727 |
| Accumulated deficit | (785,064) | (716,304) |
| Total stockholders’ equity | 451,836 | 505,664 |
| Total liabilities and stockholders’ equity | $512,905 | $566,711 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's total liabilities & equity?
- 4D Molecular Therapeutics (FDMT) reported total liabilities & equity of $512.91M in Q1 2026.
- How has 4D Molecular Therapeutics's total liabilities & equity changed year-over-year?
- 4D Molecular Therapeutics's total liabilities & equity decreased by 0.5% year-over-year, from $515.73M to $512.91M.
- What is the long-term trend for 4D Molecular Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's total liabilities & equity has grown at a 14.5% compound annual growth rate (CAGR), from $288.33M to $566.71M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about 4D Molecular Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude